Share Prices & Company Research

Stockbroking

AstraZeneca

Current Price 7222.00p Bid 7219.00p Ask 7222.00p Change -0.50%
Last Updated: 09/12/2019 17:47. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

AstraZeneca plc is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Financial Highlights Year Ended 31/12/2018

Turnover
£22,090.00m
Operating Profit
£3,387.00m
Dividend Yield
3.01
Dividend Per Share
215.20
Dividend Cover
0.78
P/E Ratio
42.69

Key Personnel

Pascal Claude Roland Soriot
Chief Executive Officer
Marc Pierre Jean Dunoyer
Chief Financial Officer
Leif Valdemar Johansson
Non-Executive Chairman
Sherilyn Dawn McCoy
Non-Executive Director
Tony Shu Kam Mok
Non-Executive Director
Prof Sabera Nazneen Rahman
Non-Executive Director
Marcus Wallenberg
Non-Executive Director
Michel Roger Demaré
Non-Executive Director
Deborah DiSanzo
Non-Executive Director
Graham Andrew Chipchase
Non-Executive Director
Philip Arthur John Broadley
Non-Executive Director
Prof Geneviève Bernadette Berger
Non-Executive Director

Stock Details

EPIC
AZN
ISIN
GB0009895292
Shares in Issue
1,311,913,268
Market cap
£95,218.67m

Analyst Views (13)

Strong Buy
 
76.92%
Buy
 
0.00%
Hold
 
7.69%
Sell
 
7.69%
Strong Sell
 
7.69%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
7222.00p
Bid Price
7219.00p
Ask Price
7222.00p
Volume
2596829
Change Today
-36.00p
% Change Today
-0.50%
Open
7263.00p
Previous Close
7222.00p
Intraday High
7277.00p
Intraday Low
7194.00p
52 Week High
7646.00p
52 Week Low
5312.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

AstraZeneca Intra-day Chart

AstraZeneca News

News in this section is provided by AJ Bell

AstraZeneca to sell rights to schizophrenia, bipolar disorder drugs to Cheplapharm for up to $41m 03 Dec 2019 | 08:04 AstraZeneca lung cancer drug granted priority review in US 29 Nov 2019 | 07:17 Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLC 27 Nov 2019 | 08:50 Broker Forecast - Bryan Garnier issues a broker note on AstraZeneca PLC 25 Nov 2019 | 10:20 Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC 22 Nov 2019 | 11:40 AstraZeneca diabetes drug approved by European Commission 15 Nov 2019 | 07:42 AztraZeneca, MSD neurofibromatosis drug application accepted, granted priority review in US 14 Nov 2019 | 07:36 AstraZeneca announces positive results for lupus drug from clinical trial 12 Nov 2019 | 07:35 UK stocks claw-back some losses, but still close down on the day 11 Nov 2019 | 16:39 UK stocks accelerate to the downside at midday 11 Nov 2019 | 12:07 FTSE opens 0.5% down amid escalation in Hong Kong tensions 11 Nov 2019 | 09:01 AstraZeneca's drug to treat anaemia in kidney disease patients meets primary goal 11 Nov 2019 | 07:30 AstraZeneca reports positive trial results for drug to treat anaemia in kidney disease patients 08 Nov 2019 | 07:58 Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC 30 Oct 2019 | 08:00 AstraZeneca sells rights to schizophrenia and bipolar drugs in Europe and Russia to Cheplapharm 30 Oct 2019 | 07:45 Broker Forecast - Kepler Cheuvreux issues a broker note on AstraZeneca PLC 29 Oct 2019 | 10:50 Broker Forecast - UBS issues a broker note on AstraZeneca PLC 29 Oct 2019 | 09:40 Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLC 25 Oct 2019 | 08:40 UK market boosted by AstraZeneca, Aveva results 24 Oct 2019 | 16:36 FSTE gains ground on AstraZeneca sales while RBS slips 24 Oct 2019 | 12:00 AstraZeneca upgrade lifts FTSE 100; RBS slumps on operating loss 24 Oct 2019 | 09:21 AstraZeneca upgrades sales guidance following 16% growth in Q3 24 Oct 2019 | 07:45 UK stocks open 0.6% higher after key Brexit vote delayed 21 Oct 2019 | 08:55 AstraZeneca drug approved in US to reduce risk of heart failure in type-2 diabetes patients 21 Oct 2019 | 07:31 UK stocks hold onto gains following Brexit breakthrough 17 Oct 2019 | 16:34 UK stocks boosted by news of Brexit breakthrough 17 Oct 2019 | 13:22 FTSE flat as traders watch for Brexit clarity 17 Oct 2019 | 09:59 AstraZeneca's breast cancer drug granted priority review in US 17 Oct 2019 | 08:20 Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC 15 Oct 2019 | 09:20 UK stocks rally as fears over US economy ease 04 Oct 2019 | 16:43

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
7,421.0
7,615.0
Intangible Assets & Goodwill
33,666.0
38,013.0
Investments & Other Non-Current Assets
3,973.0
4,576.0
Total Non-Current Assets
45,060.0
50,204.0
Inventory
2,890.0
3,035.0
Trade & Receivables
5,574.0
5,009.0
Cash & Receivables
4,831.0
3,324.0
Other Current Assets & Assets Held for Resale
2,296.0
1,782.0
Total Assets
60,651.0
63,354.0

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
16,292.0
16,383.0
Long Term Liabilities
30,315.0
30,329.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
46,607.0
46,712.0

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
14,044.0
16,642.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
317.0
317.0
Minority Interests
1,576.0
1,682.0
Retained Earnings
5,683.0
8,221.0
Share Premium Account
4,427.0
4,393.0
Other Equity
2,041.0
2,029.0
Total Equity
14,044.0
16,642.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
2,618.0
3,578.0
Cashflow Before Financing
3,581.0
1,250.0
Increase / Decrease in Cash
1,537.0
-1,686.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
22,090.0
22,465.0
Cost of Sales
4,936.0
4,318.0
Gross Profit
17,154.0
18,147.0
Operating Profit
3,387.0
3,677.0
Pre-Tax Profit
1,993.0
2,227.0
Profit / Loss for the Year
2,050.0
2,868.0

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H1 Dividend
08 Aug 2019
09 Sep 2019
H2 Dividend
28 Feb 2019
27 Mar 2019
H1 Dividend
09 Aug 2018
10 Sep 2018
H2 Dividend
15 Feb 2018
19 Mar 2018
H1 Dividend
10 Aug 2017
11 Sep 2017
H2 Dividend
16 Feb 2017
20 Mar 2017
H1 Dividend
11 Aug 2016
12 Sep 2016
H2 Dividend
18 Feb 2016
21 Mar 2016
H1 Dividend
13 Aug 2015
14 Sep 2015
H2 Dividend
19 Feb 2015
23 Mar 2015
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.